Results 151 to 160 of about 57,323 (255)

Targeting FAR1 to inhibit intestinal macrophage ferroptosis: repurposing irinotecan as a novel sepsis therapy. [PDF]

Apoptosis
Deng H, Wang W, Li Q, Xiang X, Zhu Y, Zhang Z, Zhou X, Wu Y, Zhang J, Liu L, Li T.   +10 more
europepmc   +1 more source

Payload‐Based Clinical Pharmacology Review of Approved Antibody–Drug Conjugates: Commonalities and Considerations for Streamlined Development

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 614-638, September 2026.
Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the potency of a cytotoxic drug. Thirteen ADCs, utilizing seven unique cytotoxic payloads and targeting 11 distinct antigens, are currently approved by the US Food and Drug Administration as of June 2025, representing a rapidly growing and highly promising class of anticancer ...
Sijie Lu, Qingqing Xiao, Lixuan Qian, Siyuan Sun, Zhu Zhou, Michael Z. Liao, Chunze Li   +6 more
wiley   +1 more source

Therapeutic Effects of Ceranib-2 and Irinotecan Combination on Colon Cancer. [PDF]

Curr Issues Mol Biol
Selvi O, Vejselova Sezer C, İzgördü H, Kutlu HM.   +3 more
europepmc   +1 more source

Reactivation of hepatitis B after irinotecan

, 2004
Objective: To analyse the incidence of hepatitis B reactivation following treatment with irinotecan-based combined chemotherapy and the outcomes of patients with hepatitis B reactivation.
Kwok, CCH, Lui, LCY, Yau, CC, Wong, WM, Lai, CL, Au, GKH, Chan, RTT   +6 more
core  

Manufacturing cost analysis and exploratory economic evaluation of natural killer cell immunotherapy for paediatric solid tumors

Clinical &Translational Immunology, Volume 15, Issue 9, 2026.
Exploratory economic evaluation of allogeneic NK‐cell therapy for paediatric solid tumors, highlighting treatment costs and the clinical benefit required for cost‐effectiveness. Figure made in ©BioRender—biorender.com. Abstract Objectives Natural killer (NK) cell therapy is a promising allogeneic, off‐the‐shelf immunotherapy for solid tumors, yet ...
Sabera Tabassum Wahid, Melissa Elliott, Yufan Wang, Wayne Nicholls, Natacha Omer, Fernando Souza‐Fonseca‐Guimaraes, Haitham Tuffaha   +6 more
wiley   +1 more source

Deciphering the Formulation-Dependent Neurotoxicity of Irinotecan: An Integrated Pharmacovigilance and Mechanistic Study. [PDF]

J Biochem Mol Toxicol
Shen C, Ma W, Lu J, Tang Y, Cao W.
europepmc   +1 more source

Risk factors for irinotecan-induced hepatotoxicity: a retrospective cohort study. [PDF]

Front Oncol
Alherz FA, Alnakhli AM, Alqarni AM, Alshammari AF, Ruwayi AM, Alyamani RM, Al-Salloum H, Al-Yamani MJ, Shuweihdi F.   +8 more
europepmc   +1 more source

Lonicerae Japonicae Flos as a Dietary Natural Product: Bioactive Constituents, Gut Health Modulation, and Therapeutic Potential in Ulcerative Colitis and Colorectal Cancer

Food Science &Nutrition, Volume 14, Issue 9, September 2026.
Bioactive constituents, mechanisms of action, and potential applications of Lonicerae Japonicae Flos as a dietary natural product for promoting gut health and managing ulcerative colitis and colorectal cancer. ABSTRACT Lonicerae Japonicae Flos (LJF), a traditional Chinese herb with applications in both medicine and nutrition, has emerged as a promising
Xiaoyu Huang, Letian Zhang, Zenghui Shi, Ni Zhu, Yifei Liu, Yanhong Zhou   +5 more
wiley   +1 more source

Engineered human adipose-derived stem cells delivering carboxylesterase and TRAIL for castration-resistant prostate cancer: Translational synthesis. [PDF]

Investig Clin Urol
Kim JH, Lee SH, Song YS.
europepmc   +1 more source

Transcriptome‐Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy of Overall Survival Following Adjuvant Treatment

International Journal of Cancer, Volume 159, Issue 5, Page 1322-1336, 1 September 2026.
Outcomes after resection of pancreatic ductal adenocarcinoma remain highly variable, and existing prognostic models lack sufficient accuracy. Here, the authors aimed to improve survival prediction by integrating transcriptome‐based subtyping into a validated clinical model and applying it to a multicenter real‐world cohort of fresh‐frozen resection ...
Marjolein F. Lansbergen, Vincent R. Lanting, Paul Manoukian, Marc G. Besselink, Geert Kazemier, Ignace H. J. T. de Hingh, Mike S. L. Liem, Casper H. J. van Eijck, Erwin van der Harst, Vincent E. de Meijer, Ronald M. van Dam, Martijn W. J. Stommel, Jan Koster, Michael W. T. Tanck, Arantza Fariña Sarasqueta, Joanne Verheij, Frederike Dijk, Johanna W. Wilmink, Maarten F. Bijlsma, Hanneke W. M. van Laarhoven, for the Dutch Pancreatic Cancer Group   +20 more
wiley   +1 more source